Table 3.
Influence of compound 20, and reference drugs on the growth of the individual tumour cell lines; median growth inhibitory (GI50, µM).
| Subpanel tumour cell lines | GI50 (µM) |
|||||
|---|---|---|---|---|---|---|
|
20 (799156/1)a |
Celecoxib (719627)a |
Erlotinib (718781)a |
Gefitinib (759856)a |
Sorafenib (747971)a |
Vismodegib (755986)a |
|
| Leukaemia | ||||||
| CCRF-CEM | 0.078 | 12.58 | 50.12 | 0.398 | 1.99 | 31.62 |
| HL-60(TB) | 0.164 | 15.85 | 25.12 | 1.0 | 1.58 | 31.62 |
| K-562 | 0.604 | 10.00 | 31.62 | 2.51 | 3.16 | 31.62 |
| MOLT-4 | 0.164 | 15.85 | 25.12 | 1.995 | 3.16 | 31.62 |
| PRMI-8226 | 0.297 | 3.98 | 25.12 | 6.31 | 1.58 | 31.62 |
| SR | 0.063 | 15.85 | 10.00 | 3.16 | 3.16 | 39.81 |
| Non-Small Cell Lung Cancer | ||||||
| A549/ATCC | 0.402 | 15.85 | 10.00 | 2.51 | 3.16 | 39.81 |
| EKVX | 0.162 | 19.95 | 0.199 | 0.0501 | 2.51 | 39.81 |
| HOP-62 | 0.085 | 63.09 | 15.85 | 3.16 | 1.99 | 79.43 |
| HOP-92 | 0.491 | NTb | 3.98 | 0.316 | 1.58 | 25.12 |
| NCI-H226 | 0.073 | NTb | 39.81 | 3.98 | 1.99 | 50.12 |
| NCI-H23 | 0.446 | 15.85 | 31.62 | 2.51 | 1.99 | 50.12 |
| NCI-H322M | 0.228 | 19.95 | 0.10 | 0.063 | 2.51 | 100 |
| NCI-H460 | 0.113 | 15.85 | 6.31 | 3.16 | 2.51 | 39.81 |
| NCI-H522 | 0.395 | NTb | 1.00 | 1.0 | 1.99 | 25.12 |
| Colon Cancer | ||||||
| COLO 205 | 0.269 | 15.85 | 50.12 | 7.94 | 1.99 | 39.81 |
| HCC-2998 | 0.301 | 15.85 | 79.43 | 2.51 | 3.16 | 39.81 |
| HCT-116 | 0.121 | 50.01 | 6.31 | 3.16 | 1.58 | 50.12 |
| HCT-15 | 0.092 | 15.85 | 3.98 | 3.98 | 2.51 | 31.62 |
| HT29 | 0.297 | 15.85 | 63.09 | 3.98 | 1.99 | 25.12 |
| KM12 | 0.404 | 15.85 | 79.43 | 10.0 | 1.58 | 31.62 |
| SW-620 | 0.387 | 15.85 | 79.43 | 5.011 | 2.51 | 63.09 |
| CNS Cancer | ||||||
| SF-268 | 0.0789 | 15.85 | 15.84 | 2.51 | 2.51 | 39.81 |
| SF-295 | 0.200 | 15.85 | 15.84 | 10.0 | 1.58 | 31.62 |
| SF-539 | 0.244 | 19.95 | 19.95 | 10.0 | 1.58 | 50.12 |
| SNB-19 | 0.428 | 19.95 | 12.58 | 3.16 | 3.16 | 63.09 |
| SNB-75 | 0.228 | 15.85 | 12.58 | 5.011 | 3.16 | 25.12 |
| U251 | 0.137 | 15.85 | 25.12 | 3.16 | 1.99 | 50.12 |
| Melanoma | ||||||
| LOX IMVI | 0.0997 | 19.95 | 6.31 | 3.16 | 1.58 | 39.81 |
| MALME-3M | 0.44 | 19.95 | 1.58 | 3.98 | 1.99 | 39.81 |
| M14 | 0.171 | 63.09 | 6.31 | 1.995 | 1.99 | 31.62 |
| MDA-MB-435 | 0.623 | 15.85 | 19.95 | 3.16 | 1.58 | 31.62 |
| SK-MEL-2 | 0.307 | 15.85 | 6.31 | 10.0 | 1.99 | 39.81 |
| SK-MEL-28 | 0.340 | 15.85 | 50.12 | 3.16 | 2.51 | 39.81 |
| SK-MEL-5 | 0.223 | 15.85 | 19.5 | 3.16 | 1.58 | 25.12 |
| UACC-257 | 0.340 | 19.95 | 100 | 2.51 | 1.99 | 50.12 |
| UACC-62 | 0.234 | 15.85 | 3.16 | 1.995 | 1.58 | 31.62 |
| Ovarian Cancer | ||||||
| IGROV1 | 0.196 | 15.85 | 0.316 | 3.16 | 2.51 | 100 |
| OVCAR-3 | 0.125 | 15.85 | 3.98 | 5.011 | 3.16 | 50.12 |
| OVCAR-4 | 0.063 | 12.58 | 10.00 | 6.31 | 3.16 | 39.81 |
| OVCAR-5 | 6.48 | 19.95 | 7.94 | 3.98 | 3.16 | 100 |
| OVCAR-8 | 0.25 | 19.95 | 7.94 | 0.631 | 3.16 | 31.62 |
| NCI/ADR-RES | 0.324 | 15.85 | 7.94 | 1.26 | 2.51 | 31.62 |
| SK-OV-3 | 0.251 | 19.95 | 0.50 | 1.0 | 2.51 | NTb |
| Renal Cancer | ||||||
| 786-0 | 0.182 | 39.81 | 10.00 | 3.16 | 3.16 | NTb |
| A498 | 9.81 | 15.85 | 2.51 | 0.631 | 2.51 | 31.62 |
| ACHN | 0.117 | 15.85 | 0.199 | 0.158 | 2.51 | 39.81 |
| CAKI-1 | 0.104 | 19.95 | 0.199 | 0.5012 | 3.16 | 79.43 |
| RXF 393 | 0.271 | 15.85 | 3.98 | 3.16 | 2.51 | 25.12 |
| SN12C | 0.354 | 15.85 | 1.58 | 1.258 | 2.51 | 39.81 |
| TK-10 | 0..207 | 19.95 | 0.251 | 0.794 | 3.98 | 63.09 |
| UO-31 | 0.139 | 15.85 | 1.00 | 1.584 | 2.51 | 31.62 |
| Prostate Cancer | ||||||
| PC-3 | 0.319 | 12.58 | 39.81 | 5.011 | 1.99 | 25.12 |
| DU-145 | 0.144 | 15.85 | 1.99 | 1.584 | 3.16 | 50.12 |
| Breast Cancer | ||||||
| MCF7 | 0.253 | 15.85 | 100.00 | 5.011 | 2.51 | 31.62 |
| MDA-MB-231/ATCC | 0.308 | 15.85 | 6.31 | 3.98 | 1.26 | 19.95 |
| HS 578 T | 11.7 | 19.95 | 6.31 | 7.94 | 2.51 | 79.43 |
| BT-549 | 0.346 | 19.95 | 31.62 | 3.16 | 3.16 | NTb |
| T-47D | 0.39 | 15.85 | 3.98 | 7.94 | 1.58 | 31.62 |
| MDA-MB-468 | 0.203 | NTb | 0.126 | 0.01258 | 1.99 | 19.95 |
bNT: Not tested.